VarmX and Rentschler Biopharma partner to advance novel coagulation therapy toward Phase 3 and commercialization

VarmX and Rentschler Biopharma expand collaboration from early development to late ‑ stage and commercial manufacturing of VMX-C001 VMX ‑ C001 ...
Worcester Business Journal

Rentschler Biopharma to produce blood coagulation drug for global testing

Rentschler Biopharma, a Germany-based biopharmaceuticals manufacturer with a facility in Milford, is set to produce a novel ...
Contract Pharma

Rentschler Biopharma, VarmX Partner on Coagulation Therapy

Rentschler to manufacture VarmX’s VMX-C001 for Phase 3 development and potential commercialization.
BioProcess International

Rentschler Biopharma announces partnership with VarmX to advance novel coagulation therapy

Contract development and manufacturing organization (CDMO) Rentschler Biopharma has announced a partnership with ...
FierceBiotech

First Clinical Trial Site Initiated in CSL Behring Phase II/III Pivotal Study of Recombinant Fusion Protein Linking Coagulation

First Clinical Trial Site Initiated in CSL Behring Phase II/III Pivotal Study of Recombinant Fusion Protein Linking Coagulation Factor IX With Recombinant Albumin VIENNA, January 12, 2012, 2012 ...
Business Wire

LFB SA Initiates Global Phase 3 Clinical Trial of New Coagulation Factor VIIa (Recombinant) in Patients with Hemophilia A and B

FRAMINGHAM, Mass.--(BUSINESS WIRE)--LFB SA, through its rEVO Biologics subsidiary, announced today initiation of the global Phase 3 program for LR769, a novel recombinant form of human Factor VIIa, in ...
Business Wire

Coagulation Testing Market 2020 - 2024: Post-Pandemic Industry Planning Structure | Technavio

LONDON--(BUSINESS WIRE)--The coagulation testing market is expected to grow by USD 991.28 million during 2020-2024, according to Technavio. The report offers a detailed analysis of the impact of COVID ...